Probiotics as efficient immunopotentiators: Translational role in cancer prevention

Indian Journal of Medical Research

Volumn 138, Issue NOV, 2013, Pages 808-814

  Shida, Kan ^a   Nomoto, Koji ^a  

^a YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

Author keywords

Cancer prevention; Immune modulation; Interleukin (IL) 12; Lactobacillus casei Shirota (LcS); Natural killer (NK) cell; Probiotic

Indexed keywords

EPIRUBICIN; GALACTOSE OLIGOSACCHARIDE; INTERLEUKIN 12; PROBIOTIC AGENT; SYNBIOTIC AGENT;

BLADDER CANCER; CANCER PREVENTION; COLORECTAL CANCER; HUMAN; IMMUNE RESPONSE; IMMUNOPOTENTIATION; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INTESTINE FLORA; LACTOBACILLUS CASEI; MACROPHAGE; MULTICENTER STUDY (TOPIC); NATURAL KILLER CELL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; IMMUNE SYSTEM; IMMUNOMODULATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; RISK BENEFIT ANALYSIS;

ADJUVANTS, IMMUNOLOGIC; GASTROINTESTINAL TRACT; HUMANS; INTERLEUKIN-12; KILLER CELLS, NATURAL; LACTOBACILLUS CASEI; MICROBIOTA; NEOPLASMS; PROBIOTICS;

EID: 84891714344     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005; 307: 1915-20.
2. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006; 7: 688-93.
3. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology 2009; 136: 65-80.
4. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512-9.
5. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005; 307: 1920-5.
6. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9: 313-23.
7. Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Microb Rev 2003; 16: 658-72.
8. Damaskos D, Kolios G. Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. Br J Clin Pharmacol 2008; 65: 453-67.
9. Penders J, Stobberingh EE, van den Brandt PA, Thijs C. The role of the intestinal microbiota in the development of atopic disorders. Allergy 2007; 62: 1223-36.
10. Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008; 3: 213-23.
11. Zhu Y, Michelle Luo T, Jobin C, Young HA. Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett 2011; 309: 119-27.
12. Azcarate-Peril MA, Sikes M, Bruno-Barcena JM. The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer? Am J Physiol Gastrointest Liver Physiol 2011; 301: G401-24.
13. Akaza H. Prostate cancer chemoprevention by soy isoflavones: role of intestinal bacteria as the "second human genome". Cancer Sci 2012; 103: 969-75.
14. Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 2011; 6: e16393.
15. Shen XJ, Rawls JF, Randall T, Burcal L, Mpande CN, Jenkins N, et al. Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut Microbes 2010; 1: 138-47.
16. Shida K, Nanno M. Probiotics and immunology: separating the wheat from the chaff. Trends Immunol 2008; 29: 565-73.
17. O'Flaherty S, Saulnier DM, Pot B, Versalovic J. How can probiotics and prebiotics impact mucosal immunity? Gut Microbes 2010; 1: 293-300.
18. Shida K, Nanno M, Nagata S. Flexible cytokine production by macrophages and T cells in response to probiotic bacteria: a possible mechanism by which probiotics exert multifunctional immune regulatory activities. Gut Microbes 2011; 2: 109-14.
19. Rafter J. Lactic acid bacteria and cancer: mechanistic perspective. Br J Nutr 2002; 88 (Suppl 1): S89-94.
20. Rafter J, Bennett M, Caderni G, Clune Y, Hughes R, Karlsson PC, et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am J Clin Nutr 2007; 85: 488-96.
21. Pala V, Sieri S, Berrino F, Vineis P, Sacerdote C, Palli D, et al. Yogurt consumption and risk of colorectal cancer in the Italian European prospective investigation into cancer and nutrition cohort. Int J Cancer 2011; 129: 2712-9.
22. Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. Eur Urol 1995; 27: 104-9.
23. Naito S, Koga H, Yamaguchi A, Fujimoto N, Hasui Y, Kuramoto H, et al. Prevention of recurrence with epirubicin and Lactobacillus casei after transurethral resection of bladder cancer. J Urol 2008; 179: 485-90.
24. Ishikawa H, Akedo I, Otani T, Suzuki T, Nakamura T, Takeyama I, et al. Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors. Int J Cancer 2005; 116: 762-7.
25. Yuki N, Watanabe K, Mike A, Tagami Y, Tanaka R, Ohwaki M, et al. Survival of a probiotic, Lactobacillus casei strain Shirota, in the gastrointestinal tract: selective isolation from faeces and identification using monoclonal antibodies. Int J Food Microbiol 1999; 48: 51-7.
26. Matsumoto K, Takada T, Shimizu K, Moriyama K, Kawakami K, Hirano K, et al. Effects of a probiotic fermented milk beverage containing Lactobacillus casei strain Shirota on defecation frequency, intestinal microbiota, and the intestinal environment of healthy individuals with soft stools. J Biosci Bioeng 2010; 110: 547-52.
27. Nanno M, Kato I, Kobayashi T, Shida K. Biological effects of probiotics: what impact does Lactobacillus casei shirota have on us? Int J Immunopathol Pharmacol 2011; 24: 45S-50S.
28. Nomoto K. Immunoregulatory functions of probiotics. Biosci Microflora 2000; 19: 1-8.
29. Kato I, Kobayashi S, Yokokura T, Mutai M. Antitumor activity of Lactobacillus casei in mice. Gann 1981; 72: 517-23.
30. Kato I, Yokokura T, Mutai M. Augmentation of mouse natural killer cell activity by Lactobacillus casei and its surface antigens. Microbiol Immunol 1984; 28: 209-17.
31. Kato I, Yokokura T, Mutai M. Correlation between increase in Ia-bearing macrophages and induction of T cell-dependent antitumor activity by Lactobacillus casei in mice. Cancer Immunol Immunother 1988; 26: 215-21.
32. Ohashi Y, Nakai S, Tsukamoto T, Masumori N, Akaza H, Miyanaga N, et al. Habitual intake of lactic acid bacteria and risk reduction of bladder cancer. Urol Int 2002; 68: 273-80.
33. Kanazawa H, Nagino M, Kamiya S, Komatsu S, Mayumi T, Takagi K, et al. Synbiotics reduce postoperative infectious complications: a randomized controlled trial in biliary cancer patients undergoing hepatectomy. Langenbecks Arch Surg 2005; 390: 104-13.
34. Sugawara G, Nagino M, Nishio H, Ebata T, Takagi K, Asahara T, et al. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. Ann Surg 2006; 244: 706-14.
35. Takagi A, Matsuzaki T, Sato M, Nomoto K, Morotomi M, Yokokura T. Enhancement of natural killer cytotoxicity delayed murine carcinogenesis by a probiotic microorganism. Carcinogenesis 2001; 22: 599-605.
36. Matsumoto S, Hara T, Nagaoka M, Mike A, Mitsuyama K, Sako T, et al. A component of polysaccharide peptidoglycan complex on Lactobacillus induced an improvement of murine model of inflammatory bowel disease and colitis-associated cancer. Immunology 2009; 128: e170-80.
37. De Preter V, Geboes K, Verbrugghe K, De Vuyst L, Vanhoutte T, Huys G, et al. The in vivo use of the stable isotope-labelled biomarkers lactose-[15N]ureide and [2H4]tyrosine to assess the effects of pro-and prebiotics on the intestinal flora of healthy human volunteers. Br J Nutr 2004; 92: 439-46.
38. Hayatsu H, Hayatsu T. Suppressing effect of Lactobacillus casei administration on the urinary mutagenicity arising from ingestion of fried ground beef in the human. Cancer Lett 1993; 73: 173-9.
39. Morotomi M, Mutai M. In vitro binding of potent mutagenic pyrolysates to intestinal bacteria. J Natl Cancer Inst 1986; 77: 195-201.
40. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000; 356: 1795-9.
41. Takeda K, Suzuki T, Shimada SI, Shida K, Nanno M, Okumura K. Interleukin-12 is involved in the enhancement of human natural killer cell activity by Lactobacillus casei Shirota. Clin Exp Immunol 2006; 146: 109-15.
42. Nagao F, Nakayama M, Muto T, Okumura K. Effects of a fermented milk drink containing Lactobacillus casei strain Shirota on the immune system in healthy human subjects. Biosci Biotechnol Biochem 2000; 64: 2706-8.
43. Morimoto K, Takeshita T, Nanno M, Tokudome S, Nakayama K. Modulation of natural killer cell activity by supplementation of fermented milk containing Lactobacillus casei in habitual smokers. Prev Med 2005; 40: 589-94.
44. Matsuzaki T, Saito M, Usuku K, Nose H, Izumo S, Arimura K, et al. A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis. J Neurol Sci 2005; 237: 75-81.
45. Shida K, Suzuki T, Kiyoshima-Shibata J, Shimada S, Nanno M. Essential roles of monocytes in stimulating human peripheral blood mononuclear cells with Lactobacillus casei to produce cytokines and augment natural killer cell activity. Clin Vaccine Immunol 2006; 13: 997-1003.
46. Nagaoka M, Muto M, Nomoto K, Matuzaki T, Watanabe T, Yokokura T. Structure of polysaccharide-peptidoglycan complex from the cell wall of Lactobacillus casei YIT9018. J Biochem 1990; 108: 568-71.
47. Shida K, Kiyoshima-Shibata J, Nagaoka M, Watanabe K, Nanno M. Induction of interleukin-12 by Lactobacillus strains having a rigid cell wall resistant to intracellular digestion. J Dairy Sci 2006; 89: 3306-17.
48. Zhang X, Rimpilainen M, Simelyte E, Toivanen P. Characterisation of Eubacterium cell wall: peptidoglycan structure determines arthritogenicity. Ann Rheum Dis 2001; 60: 269-74.
49. Tamura M, Shikina T, Morihana T, Hayama M, Kajimoto O, Sakamoto A, et al. Effects of probiotics on allergic rhinitis induced by Japanese cedar pollen: randomized double-blind, placebo-controlled clinical trial. Int Arch Allergy Immunol 2007; 143: 75-82.
50. Mitsuyama K, Matsumoto S, Yamasaki H, Masuda J, Kuwaki K, Takedatsu H, et al. Beneficial effects of Lactobacilluc casei in ulcerative colitis: a pilot study. J Clin Biochem Nutr 2008; 43: s78-81.
51. Kato I, Endo-Tanaka K, Yokokura T. Suppressive effects of the oral administration of Lactobacillus casei on type II collagen-induced arthritis in DBA/1 mice. Life Sci 1998; 63: 635-44.
52. Matsuzaki T, Nagata Y, Kado S, Uchida K, Kato I, Hashimoto S, et al. Prevention of onset in an insulin-dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei. APMIS 1997; 105: 643-9.
53. Mike A, Nagaoka N, Tagami Y, Miyashita M, Shimada S, Uchida K, et al. Prevention of B220+ T cell expansion and prolongation of lifespan induced by Lactobacillus casei in MRL/lpr mice. Clin Exp Immunol 1999; 117: 368-75.
54. Kobayashi T, Suzuki T, Kaji R, Serata M, Nagata T, Ando M, et al. Probiotic upregulation of peripheral IL-17 responses does not exacerbate neurological symptoms in experimental autoimmune encephalomyelitis mouse models. Immunopharmacol Immunotoxicol 2012; 34: 423-33.
55. Kaji R, Kiyoshima-Shibata J, Nagaoka M, Nanno M, Shida K. Bacterial teichoic acids reverse predominant IL-12 production induced by certain Lactobacillus strains into predominant IL-10 production via TLR2-dependent ERK activation in macrophages. J Immunol 2010; 184: 3505-13.